The victims fell or were swept into the ocean, according to the police, as swells pounded Sydney and other places along the country’s east coast. At least two others were missing. By Yan Zhuang ...

Having listed in Shenzhen, the Chinese battery giant filed for another listing in Hong Kong in February in a bid to grow its global presence. Gao boasted that the new Shenxing battery would power ...

OnePlus has confirmed that the OnePlus 13T will have a 6,260mAh battery and reiterated support for bypass charging. The phone will also have a 50MP main camera and a 2x telephoto camera, featuring ...

A food lover has created a giant Creme Egg that he joked weighed the 'same as a five-year-old child'. Phoenix, from the United Kingdom, often whips up vibrant and innovative recipes on his ...

The United Arab Emirates drilling giant on Thursday said the “award reinforces Adnoc Drilling’s unique position within Adnoc Group and as the region’s leading provider of advanced ...

In my view, these are the two most important factors for investors to consider when they look at this retail giant right now. One of the key growth drivers Couche-Tard investors have benefited ...

There could very soon be a new biggest credit card company in the United States. Capital One (COF) received approval from the Federal Reserve’s Board of Governors and the Office of the ...

The deal – which included an upfront payment of around $50 million and focused on the development of a pair of autologous and/or allogeneic T-cell receptor (TCR) based therapies – will come to ...

Infosys Q4 Results 2025: As April chimes in, so does Q4 results. Infosys reported a 12 percent year-on-year (YoY) fall in net profit to Rs 7,033 crore in the fourth quarter of FY25. This is ...

With the meteoric rise of Nvidia, chief executive Jensen Huang has been nicknamed a tech "rock star" and the 'Taylor Swift of tech' Computer chip giant Nvidia has once again found itself at the ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...